DiaMedica Therapeutics Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $8.6 million, compared to a net loss of $6.3 million for the same period in 2024. For the nine months ending September 30, 2025, the company incurred a net loss of $24.0 million, up from $16.5 million in the prior year. The increase in losses is attributed primarily to higher research and development (R&D) expenses, which rose to $6.4 million for the quarter and $17.9 million for the nine-month period, reflecting ongoing clinical trials and the expansion of the clinical team.
The company’s total assets increased to $57.0 million as of September 30, 2025, up from $46.3 million at the end of 2024. This growth was driven by a rise in cash and cash equivalents, which reached $3.3 million, and marketable securities, which increased to $52.0 million from $41.1 million. Shareholders’ equity also improved to $51.6 million, compared to $40.7 million at the end of the previous fiscal year, largely due to the successful completion of a private placement in July 2025 that generated approximately $30.0 million in net proceeds.
Operationally, DiaMedica is advancing its lead product candidate, DM199, through clinical trials for the treatment of preeclampsia (PE) and acute ischemic stroke (AIS). The company is currently conducting a Phase 2/3 trial, known as the ReMEDy2 trial, which aims to enroll approximately 300 participants across 100 sites globally. However, the company has faced challenges with slower-than-expected site activations and participant enrollment, attributed to staffing shortages in medical facilities and competition for research staff. To address these issues, DiaMedica has expanded its internal clinical team and is actively working to enhance site activations.
Looking ahead, DiaMedica anticipates continued operating losses as it progresses with its clinical development programs. The company expects its current cash resources to be sufficient to support its operations for at least the next 12 months, but it may require additional capital to fund ongoing and future clinical studies. The company has indicated that it may seek to raise additional funds through equity or debt financing, depending on market conditions and the outcomes of its clinical trials. As of November 10, 2025, DiaMedica had 52,077,439 voting common shares outstanding.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing DM199, a recombinant form of human tissue kallikrein-1, to treat severe ischemic diseases like acute ischemic stroke and preeclampsia. Its therapies aim to improve blood flow, reduce inflammation, and promote vascular health. The company focuses on clinical trials, regulatory approval, and strategic partnerships to address unmet medical needs in neurology and obstetrics markets worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.